1. Executive Summary
2. Market Size & Analysis: United States Pediatric Vaccine (2010 – 2024)
3. United States Pediatric Vaccine Market Share and Y–o–Y Growth (%)
4. Key Market Drivers and Inhibitors of the United States Pediatric Vaccine Market
4.1 Market Drivers
4.2 Market Inhibitors
5. United States Pediatric Vaccine Market – By Disease Indication (2010 – 2024)
5.1 Diphtheria, Tetanus & Pertussis (DTap)
5.1.1 Doses Administered (Volume)
5.1.2 Number of Children Being Vaccinated (Volume)
5.1.3 Market Size and Forecast (Value)
5.2 Hepatitis A
5.2.1 Doses Administered (Volume)
5.2.2 Number of Children Being Vaccinated (Volume)
5.2.3 Market Size and Forecast (Value)
5.3 Varicella / Chicken Pox
5.3.1 Doses Administered (Volume)
5.3.2 Number of Children Being Vaccinated (Volume)
5.3.3 Market Size and Forecast (Value)
5.4 Pneumococcal
5.4.1 Doses Administered (Volume)
5.4.2 Number of Children Being Vaccinated (Volume)
5.4.3 Market Size and Forecast (Value)
5.5 Haemophilus Influenzae Type B (HIB)
5.5.1 Doses Administered (Volume)
5.5.2 Number of Children Being Vaccinated (Volume)
5.5.3 Market Size and Forecast (Value)
5.6 Polio
5.6.1 Doses Administered (Volume)
5.6.2 Number of Children Being Vaccinated (Volume)
5.6.3 Market Size and Forecast (Value)
5.7 Rotavirus
5.7.1 Doses Administered (Volume)
5.7.2 Number of Children Being Vaccinated (Volume)
5.7.3 Market Size and Forecast (Value)
5.8 Hepatitis B
5.8.1 Doses Administered (Volume)
5.8.2 Number of Children Being Vaccinated (Volume)
5.8.3 Market Size and Forecast (Value)
5.9 Influenza Pediatric
5.9.1 Doses Administered (Volume)
5.9.2 Number of Children Being Vaccinated (Volume)
5.9.3 Market Size and Forecast (Value)
5.10 Measles, Mumps & Rubella (MMR)
5.10.1 Doses Administered (Volume)
5.10.2 Number of Children Being Vaccinated (Volume)
5.10.3 Market Size and Forecast (Value)
6. Key Companies Analysis
6.1 Sanofi Pasteur
6.1.1 Business Overview
6.1.2 Pediatric Vaccine Portfolios
6.1.3 Pedaitric Vaccine – Latest Development & Trends
6.2 GlaxoSmithKline (GSK)
6.2.1 Business Overview
6.2.2 Pediatric Vaccine Portfolios
6.2.3 Pediatric Vaccine – Latest Development & Trends
6.3 Merck & Co.
6.3.1 Business Overview
6.3.2 Pediatric Vaccine Portfolios
6.3.3 Pediatric Vaccine – Latest Development & Trends
6.4 Pfizer Inc.
6.4.1 Business Overview
6.4.2 Pediatric Vaccine Portfolios
6.4.3 Pediatric Vaccine – Latest Development & Trends
6.5 Grifols
6.5.1 Business Overview
6.5.2 Pediatric Vaccine Portfolios
6.5.3 Pediatric Vaccine – Latest Development & Trends
List of Tables:
Table 3–1: United States Pediatric Vaccines Market Share (Percent), 2010 – 2016
Table 3–2: United States Pediatric Vaccine Market Share Forecast (Percent), 2017 – 2024
List of Figures:
Figure 2–1: United States Pediatric Vaccine Market (Million US$), 2010 – 2016
Figure 2–2: United States Pediatric Vaccines Market Forecast (Million US$), 2017 – 2024
Figure 4–19: DTap Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–20: DTap Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–21: Number of Children Being Vaccinated with DTap Vaccine (in Million),2010 – 2016
Figure 4–22: Number of Children Being Vaccinated with DTap Vaccine Forecast (in Million),2017 – 2024
Figure 4–23: DTap Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–24: DTap Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–43: Hepatitis A Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–44: Hepatitis A Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–45: Number of Children Being Vaccinated with Hepatitis A Vaccine (in Million),2010 – 2016
Figure 4–46: Number of Children Being Vaccinated with Hepatitis A Vaccine Forecast (in Million),2017 – 2024
Figure 4–47: Hepatitis A Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–48: Hepatitis A Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–49: Varicella Vaccine Doses Administered (in Million), 2010–2016
Figure 4–50: Varicella Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–51: Number of Children Being Vaccinated with Varicella Vaccine (in Million),2010 – 2016
Figure 4–52: Number of Children Being Vaccinated with Varicella Vaccine Forecast (in Million),2017 – 2024
Figure 4–53: Varicella Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–54: Varicella Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–25: Pneumococcal Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–26: Pneumococcal Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–27: Number of Children Being Vaccinated with Pneumococcal Vaccine (in Million),2010 – 2016
Figure 4–28: Number of Children Being Vaccinated with Pneumococcal Vaccine Forecast (in Million),2017 – 2024
Figure 4–29: Pneumococcal Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–30: Pneumococcal Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–7: HIB Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–8: HIB Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–9: Number of Children Being Vaccinated with HIB Vaccine (in Million),2010 – 2016
Figure 4–10: Number of Children Being Vaccinated with HIB Vaccine Forecast (in Million),2017 – 2024
Figure 4–11: HIB Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–12: HIB Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–13: Polio Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–14: Polio Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–15: Number of Children Being Vaccinated with Polio Vaccine (in Million),2010 – 2016
Figure 4–16: Number of Children Being Vaccinated with Polio Vaccine Forecast (in Million),2017 – 2024
Figure 4–17: Polio Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–18: Polio Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–31: Rotavirus Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–32: Rotavirus Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–33: Number of Children Being Vaccinated with Rotavirus Vaccine (in Million),2010 – 2016
Figure 4–34: Number of Children Being Vaccinated with Rotavirus Vaccine Forecast (in Million),2017 – 2024
Figure 4–35: Rotavirus Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–36: Rotavirus Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–37: Hepatitis B Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–38: Hepatitis B Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–39: Number of Children Being Vaccinated with Hepatitis B Vaccine (in Million),2010 – 2016
Figure 4–40: Number of Children Being Vaccinated with Hepatitis B Vaccine Forecast (in Million),2017 – 2024
Figure 4–41: Hepatitis B Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–42: Hepatitis B Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–55: Influenza Pediatric Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–56: Influenza Pediatric Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–57: Number of Children Being Vaccinated with Influenza Pediatric Vaccine (in Million),2010 – 2016
Figure 4–58: Number of Children Being Vaccinated with Influenza Pediatric Vaccine Forecast (in Million),2017 – 2024
Figure 4–59: Influenza Pediatric Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–60: Influenza Pediatric Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–1: MMR Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–2: MMR Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–3: Number of Children Being Vaccinated with MMR Vaccine (in Million),2010 – 2016
Figure 4–4: Number of Children Being Vaccinated with MMR Vaccine Forecast (in Million),2017 – 2024
Figure 4–5: MMR Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–6: MMR Vaccine Market Value Forecast (in Million US$), 2017 – 2024
